Servier to build cancer drug pipeline with $2.5B purchase of Day One
French pharmaceutical firm Servier agrees to acquire U.S. biotech Day One Biopharmaceuticals for $2.5 billion. Deal provides Servier with approved pediatric brain tumor drug Ojemda and several experimental oncology therapies in clinical trials. Transaction accelerates consolidation in cancer drug development amid high M&A activity in biotech.
BioPharma Dive • Mar 7
CORPORATE ANTITRUST HEALTH
Cognizant TriZetto breach exposes health data of 3.4 million patients
TriZetto Provider Solutions, a Cognizant healthcare IT subsidiary, disclosed a data breach exposing sensitive personal and health information of over 3.4 million patients. The compromised data supports claims processing for insurers and providers. No evidence of misuse yet, but the incident exposes systemic risks in outsourced medical data handling.
BleepingComputer • Mar 7
SURVEILLANCE PRIVACY CYBERCRIME
Medtronic Unit Raises $560 Million in US IPO Priced Below Range
MiniMed Group, Medtronic's diabetes management division, completes $560 million US IPO priced below its indicated range. The spin-off focuses on continuous glucose monitors and insulin pumps, capitalizing on surging demand for diabetes tech amid portfolio streamlining.
Bloomberg • Mar 6
CORPORATE FINANCE HEALTH
UK's CMA to Review Private Dentistry Market After Price Hikes
The UK's Competition and Markets Authority initiates a market study of the £8.4 billion private dentistry sector following significant price increases, evaluating competition levels and consumer value. The probe targets potential market failures in pricing and access.
Bloomberg • Mar 5
CORPORATE ANTITRUST REGULATION
Medtronic Diabetes Unit MiniMed’s IPO Sparks Analyst Debate
Medtronic's diabetes management arm MiniMed is spinning off via IPO, prompting analyst splits on whether its growth in glucose monitors and insulin pumps justifies targeted valuation. The unit leverages data-driven devices amid booming demand for continuous monitoring tech. Debate centers on premium pricing versus competitive pressures in health tech markets.
Bloomberg • Mar 5
CORPORATE FINANCE TECH
German technology company CorTec implants second human with its brain-computer interface
CorTec successfully implanted its proprietary Brain Interchange BCI system in a second stroke patient during an FDA-approved clinical trial at Harborview Medical Center in Seattle. The procedure follows promising results from the first participant, advancing implantable neural interfaces for motor function restoration. This milestone accelerates the transition of brain-computer interfaces from research prototypes to therapeutic devices.
Robotics and Automation News • Mar 4
POSTHUMAN ROBOTICS HEALTH
In a Hotter, Wetter South, Mold Is Emerging as a Public Health Crisis
Post-Helene floods in Asheville, North Carolina, have unleashed toxic mold in rentals, exacerbating a severe housing shortage. Landlords evict tenants citing uninhabitable conditions, while underreported health impacts strain local systems. Vulnerable residents face intertwined crises of shelter scarcity and respiratory threats amid climate intensification.
Gizmodo • Mar 4
ENVIRONMENT HOUSING HEALTH